This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read MacroGenics’s 8K filing here.
About MacroGenics
MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.
Further Reading
- Five stocks we like better than MacroGenics
- How to Calculate Inflation Rate
- 3 Stocks With High Short Interest Still Near Their 52-Week Highs
- Which Wall Street Analysts are the Most Accurate?
- Financial Stocks Holding Firm Near Highs: 2 Key Players to Watch
- What is a Stock Market Index and How Do You Use Them?
- Upwork Fortifies Profitability Plan With Raised Q3 Forecasts
